Perspective Therapeutics Announces First Patient Dosed in
First patient with MC1R-positive metastatic melanoma treated with 212Pb-VMT01Preliminary data readout from dose escalation study expected Q4 2023 ...
Source: globenewswire.com
📰 Markus Puhlmann News
Page 2 - Markus Puhlmann News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Markus Puhlmann. Real-time updates on events, politics, business and more.
Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma
First patient with MC1R-positive metastatic melanoma treated with 212Pb-VMT01Preliminary data readout from dose escalation study expected Q4 2023 RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 11, 2023 ... -August 11, 2023 at 08:06 am- MarketScreener
Source: marketscreener.com
Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates
VMT-α-NET for neuroendocrine cancers and VMT01 for melanoma are both entering therapeutic trials under IND at leading US institutions. First melanoma patient screened and imaged with... | June 21, 2023
United States Thijs Spoor Markus Puhlmann Investigators At Fortis Memorial Research Institute Society Of Nuclear Medicine Perspective Therapeutics Inc
Source: marketscreener.com
Viewpoint Molecular Targeting, Inc.: Viewpoint Molecular Targeting Announces Appointment of Markus Puhlmann, MD, MBA as Chief Medical Officer
Dr. Puhlmann has over 20 years of oncology drug development experience and has spearheaded the global development and approval of multiple cancer drugsCORALVILLE, IA / ACCESSWIRE / October 4, 2022 / Viewpoint
United Kingdom Thijs Spoor Kostenloser Wertpapierhandel Markus Puhlmann National Cancer Institute Exchange Commission On
Source: finanznachrichten.de